BACKGROUND: The sequential use of tyrosine kinase inhibitors (TKI) followed by mTOR inhibitors (mTORi) has been recently established for the systemic treatment of metastatic renal cell carcinoma (mRCC). However, subsequent treatment in mTORi-refractory disease remains undetermined. We analyzed the efficacy of sunitinib re-challenge after failure of an mTORi at 2 German centers. PATIENTS AND METHODS: Thirteen patients who failed both sunitinib and an mTORi were analyzed, and all patients were re-exposed to sunitinib. Tumor assessment was performed every 2nd cycle of sunitinib or every 3 months. Tumor response was assessed according to RECIST criteria. RESULTS: Initial treatment with sunitinib was associated with a median progression free survival (PFS) of 21 months. Objective response consisted of 2 (15%) complete remissions and 7 (54%) partial remissions (PR) as best response. At the time of re-exposure, 12 of 13 (92%) patients again showed clinical benefit which was associated with a median PFS of 6.9 months and consisted of 2 (15%) PR and 10 (77%) disease stabilizations. CONCLUSIONS: In sunitinib-responsive patients, re-challenge with sunitinib has been successfully introduced after mTORi-refractory disease, underscoring the at least partially transient nature of TKI resistance in mRCC.
BACKGROUND: The sequential use of tyrosine kinase inhibitors (TKI) followed by mTOR inhibitors (mTORi) has been recently established for the systemic treatment of metastatic renal cell carcinoma (mRCC). However, subsequent treatment in mTORi-refractory disease remains undetermined. We analyzed the efficacy of sunitinib re-challenge after failure of an mTORi at 2 German centers. PATIENTS AND METHODS: Thirteen patients who failed both sunitinib and an mTORi were analyzed, and all patients were re-exposed to sunitinib. Tumor assessment was performed every 2nd cycle of sunitinib or every 3 months. Tumor response was assessed according to RECIST criteria. RESULTS: Initial treatment with sunitinib was associated with a median progression free survival (PFS) of 21 months. Objective response consisted of 2 (15%) complete remissions and 7 (54%) partial remissions (PR) as best response. At the time of re-exposure, 12 of 13 (92%) patients again showed clinical benefit which was associated with a median PFS of 6.9 months and consisted of 2 (15%) PR and 10 (77%) disease stabilizations. CONCLUSIONS: In sunitinib-responsive patients, re-challenge with sunitinib has been successfully introduced after mTORi-refractory disease, underscoring the at least partially transient nature of TKI resistance in mRCC.
Authors: I Duran; J Lambea; P Maroto; J L González-Larriba; Luis Flores; S Granados-Principal; M Graupera; B Sáez; A Vivancos; O Casanovas Journal: Target Oncol Date: 2017-02 Impact factor: 4.493
Authors: Alexandr Poprach; Zbyněk Bortlíček; Tomáš Büchler; Bohuslav Melichar; Radek Lakomý; Rostislav Vyzula; Petr Brabec; Marek Svoboda; Ladislav Dušek; Jakub Gregor Journal: Med Oncol Date: 2012-06-30 Impact factor: 3.064
Authors: Scott A North; Naveen Basappa; Joan Basiuk; Georg Bjarnason; Rodney Breau; Christina Canil; Daniel Heng; Michael A S Jewett; Anil Kapoor; Christian Kollmannsberger; Kylea Potvin; M Neil Reaume; J Dean Ruether; Peter Venner; Lori Wood Journal: Can Urol Assoc J Date: 2015 May-Jun Impact factor: 1.862
Authors: M Neil Reaume; Naveen S Basappa; Lori Wood; Anil Kapoor; Georg A Bjarnason; Normand Blais; Rodney H Breau; Christina Canil; Patrick Cheung; Henry J Conter; Sebastien J Hotte; Claudio Jeldres; Michael A S Jewett; Pierre I Karakiewicz; Christian Kollmannsberger; Francois Patenaude; Alan So; Denis Soulières; Peter Venner; Phillippe Violette; Pawel Zalewski; Heather Chappell; Scott A North Journal: Can Urol Assoc J Date: 2017-10 Impact factor: 1.862
Authors: Scott North; Naveen Basappa; Georg Bjarnason; Normand Blais; Christina Canil; Daniel Heng; Jennifer Knox; Neil Reaume; Dean Ruether; Denis Soulières; Pawel Zalewski; Peter Black; Rodney H Breau; Rodney Breau; Michael Jewett; Anil Kapoor; Jean-Baptiste Lattouf; Ronald Moore; Ricardo Rendon; Gerald Todd; Edith Pituskin; Craig Gedye; Lori Wood Journal: Can Urol Assoc J Date: 2013 Jul-Aug Impact factor: 1.862